Abstract
OHSS appears to be induced by the ovarian release vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2), causing increase vascular permeability (VP). Dopamine agonist (DA) inhibit VEGF/VEGFR2 and thereby decrease VP. The aim of this study was to determine the efficacy of non-ergot derived Dopamine agonist Quinagolide (Norprolac: Ferring Pharmaceuticals) in preventing OHSS in high risk women undergoing ICSI, and how would it affect the outcome?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
